This study looked at real-world data from over 6,700 patients with various liver conditions who were treated with semaglutide. Researchers examined how the dose and weight loss from the medication were related to the risk of developing specific liver diseases and changes in liver stiffness over time.
The main finding was that higher doses of semaglutide and greater weight loss were associated with a lower risk of steatohepatitis, alcoholic liver disease, and all-cause mortality. In a smaller group of 326 patients, liver stiffness decreased after starting semaglutide, and many patients saw a meaningful reduction in stiffness or moved to a lower fibrosis stage.
The study did not report on safety events like side effects or discontinuations. The main reason to be careful is that this is an observational study, which can show links but cannot prove that semaglutide directly causes these liver benefits. Other factors, like patient health habits, could influence the results.
What readers should realistically take from this is that semaglutide may be associated with diverse liver benefits beyond weight loss, but more research is needed. The findings are not yet practice-changing and should not be used to make personal treatment decisions.